Abstract

PurposeReporting a special clinical finding after intravitreal bevacizumab monotherapy for retinopathy of prematurity.MethodsIn a retrospective case series, the clinical courses of five premature infants with similar vitreous changes after a single dose of intravitreal bevacizumab (IVB) injection without additional laser therapy were reported.ResultsThe mean post-conceptional age at IVB injection was 39.8 ± 2.2 (range 37–43) weeks. Localized vitreous syneresis and linear fibrotic vitreous condensation occurred 8.2 ± 2.3 weeks after IVB monotherapy in our patients (15.5% of injections). The mean last post injection visit was 61.6 ± 5.3 weeks (post-conceptional age). Further regression and complete retinal vascularization occurred in all patients.ConclusionsThread-like vitreous condensation with localized vitreous liquefaction may be related to involutional ROP disease itself, combined to anti VEGF therapy and may be a predictor factor for further regression and retinal vascularization. The case series describes a successful response to anti-VEGF monotherapy with no further complications.

Highlights

  • Retinopathy of prematurity (ROP) is a disorder of neonatal retinal vascularization

  • We reported the clinical courses, fundus photographs and specifications of nine eyes of five premature infants with a similar vitreous change at the original fibrovascular ridge, developed after a single dose of intravitreal bevacizumab (IVB) for treating stage 3 with or without plus disease

  • All of the patients who were referred to the ROP clinic, Khatam-AlAnbia Ophthalmology Hospital, Mashhad, Iran, between May 2012 and June 2014 and received IVB for ROP were reviewed retrospectively and the patients with a medical record of linear fibrillar vitreous condensation, partial vitreous detachment at the site of original fibrovascular ridge or any other vitreous change after IVB injection were collected

Read more

Summary

Introduction

Ablation of peripheral avascular retina is the standard treatment method for type-I ROP [1]. There are several disadvantages to retinal laser photocoagulation including posterior synechiae, macular ectopia, and scarring of the peripheral retina and choroid, as well as the need for general anesthesia some of these complications may be the natural course of the disease [2]. This is why a safe, effective and easy-to-apply treatment is still highly sought. Bevacizumab has been applied in ROP cases, with recent

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.